This content is machine translated Metastatic colorectal carcinoma A challenging opponent With a median survival of about two years, the prognosis for metastatic colorectal cancer remains poor. New therapeutic options have brought some improvement in recent years, but major breakthroughs have…
View Post 2 min This content is machine translated Colorectal Cancer mTORC2 inhibition may be the wrong target Recent studies revealed that the mTORC2 protein – the target of some newly developed cancer drugs – is not active at all in colorectal cancer. mTORC2 activity has been detected…
View Post 7 min This content is machine translated Extensive liver metastases in colorectal cancer. Chances for treatment? Removal of colorectal liver metastases is prognostic. Oncologic and surgical technical criteria are used to assess resectability.
View Post 3 min This content is machine translated Colorectal Cancer Focus on combination therapies Triple for colorectal cancer – for the first time, studies have shown clear superiority of a triple combination of encorafenib, binimetinib and cetuximab in progressive metastatic colorectal tumors.
View Post 11 min This content is machine translated ASCO 2018 in Chicago Study news on lung, kidney and intestine KEYNOTE-042 and CARMENA: Two studies that have the potential to change practice. It’s about lung cancer – as so often lately – but also about renal cell carcinoma. Furthermore, the…
View Post 4 min This content is machine translated Colorectal Cancer Colorectal cancer diagnosis is “masked” by other diseases Conditions unrelated to cancer complicate and delay the diagnosis of colorectal cancer – even if they do not cause similar symptoms.
View Post 7 min This content is machine translated Advanced training course in clinical oncology in St. Gallen Metastatic colorectal cancer “beyond surgery”. At the advanced training course in clinical oncology in St. Gallen, there was also a symposium on colorectal carcinoma, among other topics. In an overview, Prof. Dr. med. Ralf-Dieter Hofheinz,…
View Post 4 min This content is machine translated Onco-Training St. Gallen News on metastatic colorectal cancer Metastatic colorectal cancer was the focus of an afternoon symposium in St. Gallen. Significant progress has been made in the field of colorectal cancer therapy in recent years, but this…
View Post 4 min This content is machine translated Metastatic colorectal cancer Which first-line therapy for patients with wild-type RAS? At this year’s ESMO Congress in Madrid, treatment options for metastatic colorectal cancer were also discussed. Is there an optimal strategy for patients with a wild-type RAS mutation, and would…
View Post 4 min This content is machine translated Metastatic colorectal cancer Comparison between bevacizumab and cetuximab in KRAS exon2 wild type. According to preliminary results of a large phase III trial presented at this year’s ASCO congress, bevacizumab and cetuximab (combined with FOLFOX or FOLFIRI) show similar efficacy in terms of…
View Post 3 min This content is machine translated 2nd EORTC St. Gallen Gastrointestinal Cancer Conference 2014 VEGF inhibition in metastatic colorectal cancer. The use of the VEGF inhibitor bevacizumab improves the outcome of patients with metastatic colorectal cancer regardless of the chemotherapy chosen. Recent data suggest that the duration of VEGF inhibition…
